153 related articles for article (PubMed ID: 20347575)
21. Maine law requires drug companies to provide clinical trial data.
Appell D
J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
[No Abstract] [Full Text] [Related]
22. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
23. Antiepileptic drug therapy in the United States: a review of clinical studies and unmet needs.
Pellock JM
Neurology; 1995 Mar; 45(3 Suppl 2):S17-24. PubMed ID: 7898741
[TBL] [Abstract][Full Text] [Related]
24. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
25. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
26. Contraception, pregnancy and lactation in women with epilepsy.
Yerby MS
Baillieres Clin Neurol; 1996 Dec; 5(4):887-908. PubMed ID: 9068887
[TBL] [Abstract][Full Text] [Related]
27. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
Boon WP; Moors EH; Meijer A; Schellekens H
Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
[TBL] [Abstract][Full Text] [Related]
28. Obtaining pediatric indications for new anti-epileptic drugs: how and when.
Garofalo E
Epilepsy Res; 2006 Jan; 68(1):38-42. PubMed ID: 16377135
[TBL] [Abstract][Full Text] [Related]
29. Ethical considerations.
Treiman DM
Epilepsy Res Suppl; 1993; 10():137-48. PubMed ID: 8251089
[No Abstract] [Full Text] [Related]
30. Overview of the animal health drug development and registration process: an industry perspective.
Hunter RP; Shryock TR; Cox BR; Butler RM; Hammelman JE
Future Med Chem; 2011 May; 3(7):881-6. PubMed ID: 21644833
[TBL] [Abstract][Full Text] [Related]
31. Preparing for an FDA audit.
Barnes D
Epilepsy Res Suppl; 1993; 10():245-50. PubMed ID: 8251103
[No Abstract] [Full Text] [Related]
32. Monotherapy clinical trial design.
Sachdeo R
Neurology; 2007 Dec; 69(24 Suppl 3):S23-7. PubMed ID: 18071154
[TBL] [Abstract][Full Text] [Related]
33. Medical devices on trial, Part I.
Wright D
Med Device Technol; 2002 Dec; 13(10):35-8. PubMed ID: 12575529
[TBL] [Abstract][Full Text] [Related]
34. Zonisamide in the treatment of epilepsy.
Schulze-Bonhage A
Expert Opin Pharmacother; 2010 Jan; 11(1):115-26. PubMed ID: 20001433
[TBL] [Abstract][Full Text] [Related]
35. Drug development in oncology: a regulatory perspective.
Augustus S
Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
[TBL] [Abstract][Full Text] [Related]
36. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
Shani S; Yahalom Z
Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
[No Abstract] [Full Text] [Related]
37. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
[TBL] [Abstract][Full Text] [Related]
38. Antiepileptic drugs: future development.
Porter RJ
Epilepsy Res Suppl; 1993; 10():69-77. PubMed ID: 7504494
[TBL] [Abstract][Full Text] [Related]
39. Researchers see a need for speed in EU trial approvals.
Cressey D
Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
[No Abstract] [Full Text] [Related]
40. Biosimilar insulins.
Heinemann L
Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
